Anti-VEGF therapy did not prevent conversion to neovascular AMD in fellow eyes

The use of intravitreal anti-VEGF injections did not prevent conversion from nonexudative to exudative age-related macular degeneration in the fellow eyes of patients with unilateral neovascular AMD.
“Exactly the same number of patients treated with ranibizumab or sham developed conversion within 2 years,” Clement K. Chan, MD, FACS, said at the virtual American Academy of Ophthalmology annual meeting.
It is known that patients with unilateral neovascular AMD have a significant risk for progression to neovascular disease in the fellow eye. In the MARINA, ANCHOR, SST and CATT trials,

Full Story →